were investigated, Pd-103, I-125, Yb-169, 50kVp x-rays, and 6 MV x-rays. The results are compared to recently published data calculated with the same approach when using gold nanoparticles.

Results: For BiN concentrations ranging from 7–140 mg/g, EDEF values of 1.33–7.52, 1.31–7.25, 1.04–1.84, 1.27–6.48, and 1.28–6.67, where calculated for Pd-103, I-125, Yb-169, 50 kVp, and 6 MV, respectively. Apart from the results for Pd-103, the calculated EDEFs predict higher dose enhancement due to photo-electrons when using BiNs as compared to when using gold nanoparticles.

Conclusions: The results predict that significant dose enhancement to tumour endothelial cells may be achieved by applying tumour vasculature-targeted BiNs as adjuvants to radiotherapy. BiNs may provide a low cost alternative to the potential use of gold nanoparticles for vascular dose painting or as radiosensitizers during radiotherapy.

Table: Endothelial dose enhancement due to photo electrons for various radiotherapy sources

| | EDEF due to photoelectrons from | | | | | |
| | Bismuth nanoparticles | | | Gold nanoparticles | | |
	7 mg/g	30 mg/g	140 mg/g	7 mg/g	30 mg/g	140 mg/g
Pd-103	1.33	3.00	7.52	1.42	2.81	9.46
I-125	1.31	2.34	7.25	1.26	2.10	6.12
Yb-169	1.04	1.18	1.84	1.03	1.15	1.68
50 kVp	1.27	2.17	6.48	1.25	2.08	6.05
6 MV	1.28	2.21	6.67	1.20	1.70	4.4

2153 ORAL

Impact of Electronic Treatment Scheduling and Web Based Communication Technology on Systemic Therapy Delivery at the Sunnybrook Odette Cancer Center, Toronto, Canada

S. Singh[1], B. De Mendonca[1], M. Trudeau[1], M. Cheung[1]. [1]Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto ON, Canada

Background: The Odette Cancer Centre (OCC) is the sixth largest cancer institution in North America and currently manages over 18,000 chemotherapy patient visits per year. Current barriers to efficient and effective delivery of chemotherapy included scheduling inefficiencies and staff communication. These issues were addressed via two distinct mechanisms:(1) chemotherapy scheduling tool and (2) electronic communication tool for nurses and pharmacy staff.

Methods: An electronic Chemotherapy Appointment Reservation Manager (CHARM) was developed in house. CHARM is configured to calculate treatment times based on the pharmacist chemotherapy prep, nursing time and time for drug administration. In addition a new electronic web based communication tool was developed and implemented to facilitate communication between nursing and pharmacy staff. Data were prospectively collected for 2-week intervals in both 2009 and 2010 to assess the effect of both new programs. A flow-time analysis, patient and staff satisfaction surveys were conducted comparing the two time frames.

Results: For 2009, data was collected for 381 of 796 total patients treated in the two-week period (47.9%). For 2010, data was collected for 602 of 836 total patients. An increase in year-to-year volume of 5%,was noted.

Thirty-six percent of patients started chemotherapy +/− 30 min of their scheduled time in both 2009 and 2010. However, the number of patients treated >30 mins after their scheduled appointments increased from 68 (20.7%) to 357 (71.1%). Patients receiving treatment in the correct bed assignment decreased from 45% in 2009 to 30% in 2010.

The distribution of patient arrival times was skewed with 58.1% of patients scheduled to arrive prior to 10am, 23.4% between 10−12 and only 18.4% after 12. In 2010, 69.3% of patients arrived earlier than their scheduled appointment by more than 30 minutes, with a mean arrival time of 117 minutes earlier than scheduled. Seven percent of patients arrived greater than 30 minutes late, with a mean arrival time of 49 mins late.

Time from patient registration on arrival to:	2009 (min)	2010 (min)
Patient on chemotherapy unit	33	43
Nursing approval for administration	80	85
Pharmacy approval of administration	89	94
Patient arrival in chemotherapy chair	110	137
Chemotherapy prepared	114	132
Initiation of chemotherapy	125	173

In 2010, a reduction in phone calls (for chemotherapy approval) between the nurses and pharmacy of 89% was observed. The number of chemotherapy order clarifications was similarly reduced by 91%. Nurses were more likely to agree or strongly agree that communication positively impacted on chemotherapy administration after implementation of the communication tool (80% vs. 37%).

Conclusions: Despite the implementation of CHARM, there was little change in patient flow. Possible explanations include increased patient volumes without infrastructure increases and suboptimal patient arrival patterns. To realize the full potential of the new reservation management system, adherence and redistribution of scheduled appointment times will be necessary along with proper chair placement. The online communication tool has resulted in improved flow in the chemotherapy unit as well as increased nursing satisfaction.

2154 ORAL

Survey of UK Cancer Patients, Exploring Their Internet Usage and Potential for Text Messaging Communication With Their Hospital

G. Faust[1], E. Summers[1], P. Camilleri[1]. [1]Northampton General Hospital, Department of Oncology, Northampton, United Kingdom

Background: The aim of the survey was to explore cancer patients' use of the internet and elicit their opinion regarding communication with the hospital via electronic methods.

Methods: A questionnaire was developed consisting of four questions:
1. Do you (or a carer) access the internet?
2. Would you (or a carer) be prepared to enter details about your side effects from treatment through a dedicated and secure website?
3. Do you (or a carer) have/use a mobile telephone, specifically to send/receive text messages?
4. Would you (or a carer) be prepared to allow the hospital to sent you text messages relating to your treatment?

Data was collected from 445 patients attending Northampton General Hospital for chemotherapy and/or radiotherapy during February 2011 − both by direct questioning & paper questionnaire.

Results: Answers to questions:
Q1. 322 (72%) patients have access to the internet.
Q2. 296 (67%) of those questioned would be prepared to record toxicities via website (92% of those who access the internet).
Q3. 351 (79%) have or use a mobile phone for accessing text messages.
Q4. 326 (73%) would be prepared to allow our hospital to communicate via text messages with regard to their treatment (93% of those with mobile phones).

Data relating to variation with age shows that up to 70 years old the majority of our patients (up to 85% in those patients in their 4th decade) would be willing to use these types of technology to communicate with our hospital. In those aged over 70 this proportion falls but is still >40%.

Conclusions: This study supports the hypothesis that UK patients support the introduction of electronic communications between a hospital and oncology patients receiving treatment. Under 70 years old the majority of individuals supported the use of both types of communication. Those over 70 years old were less enthusiastic but were more in favour of the use of text messages than the internet. We believe that the introduction of an electronic system to communicate with our patients, via the internet and/or text messaging, would enhance the patient's experience adding support to this type of initiative.

2155 ORAL

Tele Oncology Clinics in Rural Australia: a Cost-effective Cancer Care Model

D.A. Thaker[1], S.S. Sabesan[1], B. Van Houts[2], A. Bryett[3], I.N. Olver[4]. [1]Townsville Hospital, Medical Oncology, Townsville Queensland, Australia; [2]Qld Health, Statewide Telehealth Services, Townsville Queensland, Australia; [3]Qld Health, Statewide Telehealth Services, Brisbane Queensland, Australia; [4]Cancer Council Australia, CEO, Sydney NSW, Australia

Background: Cost benefit studies in telemedicine are often incomplete and compare establishment costs with outpatient costs only. While some studies reported marginal benefit, others found no savings. We conducted a comprehensive cost benefit analysis of tele oncology clinics at Townsville Cancer Centre (TCC) and its rural centres in North Queensland, Australia.

Methods: Data on teleoncology clinics between March 2007 and November 2010 was gathered from the Oncology Information Management system. Patient travel expense information was provided by the QLD Health patient travel office. A model proposed by Dr B L Crowe (Health Informatics Society of Australia) was used for the calculation. Factors used are shown in the table.

Results: 605 consultations were performed for 147 patients over 44 months from TCC to five satellite centres. All centres are located in remote areas with distances ranging from 400 to 1200 kms from Townsville.

54 consultations were done in the first year of the project. 129, 136 and 286 consultations were done in subsequent years respectively. 16% of patients were from indigenous community. Breast and lung cancers were the most common types (73%). Intravenous chemotherapies were given at two centres post teleconsultations.

In the first year of the project, the cost was 30% higher than the potential benefit. Again in 2009, when 3 new sites were enrolled, the cost increased by 20% over the expenses prevented. Overall in four years, the total cost was 463,748 A$, while the estimated expense prevented was 855,660 A$ resulted in a net saving of 391,912 A$.

Conclusions: Our study clearly shows that the teleoncology clinics save money to the health system and patients while providing efficient cancer care to rural Australia. It is beneficial after first year of establishment and with more than 100 consultations per year. Equipment and staffing costs are the main costs (74%) while avoidance of patient travel and urgent transfers are the key factors of the benefit (83%). Cost rises temporarily when new centres are enrolled. Overall, more consultations at multiple satellite centres give maximum benefit.

Other benefits: Time and energy saved by the patient and escort, avoid delay in seeing patient and starting treatment, reduction in clinic workload at home site, avoid unnecessary transfer and better communication with the remote doctors.

Cost of telemedicine

Type of cost	Cost per centre (A$)	Cost for six centres for four years (A$)	Total(A$)
Project establishment	6,000	6,000 × 6	36,000
Equipment	23,726	23,726 × 6	142,356
Maintenance	3,558 per centre per year	3,558 × 6 × 4	85,392
Communication	0.00	0.00	0.00
Staffing	50,000 per year for all centres	50,000 × 4	200,000
Total cost over four years			**463,748**

Expenses prevented by telemedicine

Expense	Savings (A$)
Return travel cost for patient and one relative	670,760
Overnight accommodation for patient and one relative in Townsville	60,500
Urgent Aero Medical Retrieval of four patients	52,400
Specialist travel to remote centres	72,000
Total savings over four years	**855,660**

Poster Presentations (Sun, 25 Sep, 14:00−16:30)
Oncotechnology

2156 POSTER

Effectiveness of Infrared Microspectroscopy in the Differentiation of Benign Liver Nodules From Hepatocellular Carcinoma

C. Lima[1], D.A. Maretto[2], C.A.F. Escanhoela[3], R.J. Poppi[2]. [1]State University of Campinas, Department of Internal Medicine of the Faculty of Medical Sciences, Campinas, Brazil; [2]State University of Campinas, Department of Analytical Chemistry of the Chemistry Institute, Campinas, Brazil; [3]State University of Campinas, Department of Anatomic Pathology of the Faculty of Medical Sciences, Campinas, Brazil

Background: The hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 90% of cases. The relationship between HCC and cirrhosis is well established, especially in secondary cases to infection by the B and C virus of hepatitis and consumption of alcoholic beverages. Liver nodules can be benign (regenerative or cirrhotic) or those (low-grade dysplastic and high-grade dysplastic) which may undergo transformation to HCC. Injuries to liver are defined consistently only by histological analysis. It is worth mentioning that the differential diagnosis of benign nodules and HCC is needed to define the appropriate therapy for each case. Also, early diagnosis of HCC confers a better prognosis to the patients. However, difficulties are commonly encountered in the differentiation of benign and malignant liver lesions (HCC) using conventional histological analysis, which justifies the search for other methods that contribute to correct diagnosis of different lesions.

Objective: The aim of this study was to investigate whether infrared microspectroscopy allows the differentiation of benign lesions in the liver and HCC, with the conventional histological analysis as the gold standard for such determination.

Methods: It was analyzed fragments of human liver, benign nodules or HCC, embedded in paraffin blocks of the archive of the Department of Pathology of our Institution. Histological sections of 5 μm in each case were mounted on glass slides. The fragments were analyzed in a Spotlight 400N spectrometer (Perkin Elmer, Seer Green, England). The parameters used were: image mode, 64 scans per pixel, resolution 4 cm^{-1}, spectral range of 2000 to 6000 cm^{-1}, area of 100×100 microns). The calculations were performed using the LS-SVM Toolbox for Matlab 7.8. For the development of the models, it was used 83 spectra of dysplastic or HCC nodules and 41 cirrhotic nodules. In the models that presented the most accurate classification of samples, the following pre-processing was used: second derivative, autoscale and normalization, to eliminate spectral differences caused by concentration and scattering of radiation between the samples, and orthogonal signal correction (OSC) to eliminate unnecessary information from the spectra. The support vector machines (SVM) are learning algorithms that can model data via adapted nonlinear kernel functions. It was used the SVM parameters optimization by genetic algorithm.

Results: 81% of samples were correctly classified, considering cirrhotic and HCC nodules but was not effective to differentiate cirrhotic from dysplastic nodules and dysplastic nodules from HCC.

Conclusions: The results suggest that infrared microspectroscopy is an effective method to differentiate benign lesions of liver and HCC and thus may contribute to establishing the differential diagnosis in daily practice of oncology services and clinical pathology.

2157 POSTER

Diffuse Reflectance Spectroscopy − a New Guidance Tool for Improvement of Minimal Invasive Procedures in Lung and Liver Cancer

D.J. Evers[1], R. Nachabe[2], H.M. Klomp[1], J.W. van Sandick[1], M.W. Wouters[1], D. Hompes[1], G.W. Lucassen[2], B.H.W. Hendriks[2], J. Wesseling[3], T.J.M. Ruers[1]. [1]The Netherlands Cancer Institute (NKI-AVL), Surgery, Amsterdam, The Netherlands; [2]Philips Research, Minimally Invasive Healthcare, Eindhoven, The Netherlands; [3]The Netherlands Cancer Institute (NKI-AVL), Pathology, Amsterdam, The Netherlands

Background: During diffuse reflectance spectroscopy (DRS), tissue is illuminated by a broadband white light. Subsequent alterations in the light spectrum occur due to scattering and absorption. Specific quantitative biochemical and morphological information from the examined tissue can be derived from spectral changes and provide information on cellular metabolic rate, vascularity, intra-vascular oxygenation and alterations in tissue morphology. Thus, DRS allows to make a distinction between tissues by differences on a molecular and morphological level and has the potential to be incorporated into optical tools for cancer diagnosis and therapy. We hypothesize that DRS has the ability to enhance diagnostic accuracy and to refine minimal invasive treatment of malignant lung and liver disease by improving localisation possibilities.

Methods: *Ex-vivo* analysis with a DRS system was performed on lung tissue from 10 patients and liver tissue from 14 patients. A total of 330 optical measurements were performed on 67 tissue locations of both normal and malignant lung tissue. A total of 526 optical measurements were performed on 101 tissue locations of both normal and malignant liver tissue. Tissue spectra measured from 500 to 1600 nm were analyzed and classified using a model-based analysis. Results were compared to the histological diagnosis of the measured tissue.

Results: DRS spectra yielded sensitivity and specificity figures of respectively 89 and 79% for the discrimination of normal lung tissue from malignant lung tissue. The resulting overall accuracy was 84%.

For liver tissue, sensitivity was 96% and specificity was 91%. Overall accuracy for discriminating normal liver tissue from malignant liver disease was 94%. This discriminative power was enhanced in liver tissue as compared to lung tissue due to the significant difference in bile concentration which can be measured with DRS in normal liver parenchyma compared to the malignant lesions.

Conclusion: DRS demonstrated a high accuracy for discriminating between normal tissue and malignant tissue of *ex-vivo* human lung and liver tissue. Based on presented results we conclude that DRS has the potential to enhance accuracy of minimal invasive procedures of both organs in clinical practice. A feasibility study in the clinical setting has been initiated.